Heron Therapeutics Inc (NASDAQ: HRTX) has seen a decline in its stock price by -3.19 in relation to its previous close of 1.88. However, the company has experienced a -14.95% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-27 that Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Melissa Jarel – Executive Director, Legal Craig Collard – Chief Executive Officer Ira Duarte – Executive Vice President, Chief Financial Officer Bill Forbes – Executive Vice President, Chief Development Officer Kevin Warner – Senior Vice President, Medical Affairs, Strategy and Engagement Conference Call Participants Brandon Folkes – Rodman & Renshaw Serge Belanger – Needham Carl Byrnes – Northland Capital Markets Clara Donald – Jefferies Operator Good day, and thank you for standing by, and welcome to the Heron Therapeutics Q4 2024 Conference Call. At this time, all participants are in a listen-only mode.
Is It Worth Investing in Heron Therapeutics Inc (NASDAQ: HRTX) Right Now?
Additionally, the 36-month beta value for HRTX is 1.38. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for HRTX is 150.94M and currently, short sellers hold a 21.54% ratio of that float. The average trading volume of HRTX on April 11, 2025 was 1.73M shares.
HRTX’s Market Performance
HRTX stock saw a decrease of -14.95% in the past week, with a monthly decline of -24.48% and a quarterly a decrease of 13.75%. The volatility ratio for the week is 11.23%, and the volatility levels for the last 30 days are 7.32% for Heron Therapeutics Inc (HRTX). The simple moving average for the past 20 days is -17.78% for HRTX’s stock, with a -9.51% simple moving average for the past 200 days.
Analysts’ Opinion of HRTX
Many brokerage firms have already submitted their reports for HRTX stocks, with Rodman & Renshaw repeating the rating for HRTX by listing it as a “Buy.” The predicted price for HRTX in the upcoming period, according to Rodman & Renshaw is $7 based on the research report published on June 13, 2024 of the previous year 2024.
CapitalOne, on the other hand, stated in their research note that they expect to see HRTX reach a price target of $6. The rating they have provided for HRTX stocks is “Overweight” according to the report published on April 23rd, 2024.
Needham gave a rating of “Buy” to HRTX, setting the target price at $5 in the report published on March 13th of the previous year.
HRTX Trading at -11.40% from the 50-Day Moving Average
After a stumble in the market that brought HRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.69% of loss for the given period.
Volatility was left at 7.32%, however, over the last 30 days, the volatility rate increased by 11.23%, as shares sank -21.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.98% upper at present.
During the last 5 trading sessions, HRTX fell by -14.95%, which changed the moving average for the period of 200-days by -42.77% in comparison to the 20-day moving average, which settled at $2.2135. In addition, Heron Therapeutics Inc saw 18.95% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for HRTX
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.69 for the gross margin
The net margin for Heron Therapeutics Inc stands at -0.09. The total capital return value is set at -0.08.
Based on Heron Therapeutics Inc (HRTX), the company’s capital structure generated 1.23 points at debt to capital in total, while cash flow to debt ratio is standing at -0.13.
Currently, EBITDA for the company is -5.06 million with net debt to EBITDA at -26.96. When we switch over and look at the enterprise to sales, we see a ratio of 2.79. The receivables turnover for the company is 1.95for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.29.
Conclusion
In conclusion, Heron Therapeutics Inc (HRTX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
